The changing landscape of NSCLC treatment provides numerous novel options, but how can they best be incorporated into clinical practice to improve patient outcomes?
Patients requiring extended thromboprophylaxis after a first episode of cancer-related venous thromboembolism can be given a low dose of the factor X inhibitor apixaban.
What are the underlying mechanisms that cause radiation-induced lung injury, the most common adverse effect of thoracic radiotherapy? What is the prognosis and how can it be treated?
MET exon 14 skipping mutations occur in 3–4% of patients with NSCLC and are associated with poor response to chemotherapy. MET inhibitors have shown great promise – learn about these and other agents being investigated.
TNF inhibitors do not adversely affect survival in patients with rheumatoid arthritis who begin treatment within 3 years of an early-stage colorectal, lung, or prostate cancer diagnosis.
In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.
This content is intended only for US-based healthcare providers.
A woman who underwent mastectomy and chemotherapy for breast cancer subsequently developed chest pain and dyspnea. Would you have considered pleural mesothelioma as the cause?
Pneumonitis related to ICI therapy typically occurs within the first few months of treatment, but this lung cancer patient experienced the adverse event 2.5 months after discontinuing pembrolizumab, underscoring the need for long-term vigilance.
Fatal outcomes in three cases, despite aggressive treatment, emphasize the poor prognosis of fulminant myocarditis related to immune checkpoint inhibitor therapy.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy …
During the European Society for Medical Oncology (ESMO) 2024 scientific meeting, multiple groundbreaking trials from organ-specific studies were reported. Additionally, results from early clinical trials in the tumor-agnostic space, such as the …
The development of antibody–drug conjugates (ADCs) from concept to clinical use reflects the significant progress in cancer treatment. Inspired by Paul Ehrlich's early 20th-century notion of "magic bullets"—agents designed to target …
Based on the evidence of a significant reduction in lung cancer (LC)-related mortality in high-risk individuals [ 1 , 2 ], low-dose Computed Tomography (LDCT) lung cancer screening (LCS) is increasingly endorsed by national stakeholders and …
The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.
In this interactive webinar, experts discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.
This content is intended only for US-based healthcare providers.
Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.
A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.
Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy …
Lung cancer is the most commonly diagnosed cancer and most frequent cause of cancer-related death worldwide, with around 2.5 million cases and 1.8 million deaths reported in 2022 [ 1 , 2 ]. In Canada, for example, an estimated 31,000 new lung …
Thymic epithelial tumors (TET) are a heterogeneous group including thymomas, thymic carcinomas (TC), and thymic neuroendocrine tumors (TNET) [ 1 ]. The incidence for all TET patients is reported as 1.3–3.2 per million. In a recent study, the …
